Lipocine Inc.
Proprietary drug formulation and delivery technology platform for oral pharmaceuticals
- Sector
- Biotech
- Headquarters
- SALT LAKE CITY, X1
- Founded
- 2011
- Latest Form D
- Aug 2013
- Total capital
- $38M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $38M
- 2 Form D · last Aug 2013
- 159 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 31
- 9 pending · first 2022
- Rank in peer group#25 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$38M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#25 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mahesh V. PatelResearcherExecutive Officer, DirectorLinked by 6 patents
- Gerald K. SimmonsExecutive OfficerNamed in SEC Form D filings
- Gordhan K. PatelDirectorNamed in SEC Form D filings
- John W. HiguchiDirectorNamed in SEC Form D filings
- Robert K. MerrellExecutive OfficerNamed in SEC Form D filings
- Srinivasan K. VenkateshwaranExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- William I. HiguchiDirectorNamed in SEC Form D filings
What it has protected
USPTO · 31 granted of 40- Granted3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System DisordersUSPTOUS 12,714,717
- GrantedFixed Dose Oral Testosterone Undecanoate Compositions and Use ThereofUSPTOUS 12,691,057
- PendingOral Brexanolone Compositions and Methods of Preparation and UseUSPTOApplication 19564966
Show all 40 patent records
- 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System DisordersAug 25, 2026 · US 12,714,717Granted
- Fixed Dose Oral Testosterone Undecanoate Compositions and Use ThereofJul 28, 2026 · US 12,691,057Granted
- Oral Brexanolone Compositions and Methods of Preparation and UseJul 16, 2026 · Application 19564966Pending
- Oral Brexanolone Compositions and Methods of Preparation and UseJun 4, 2026 · Application 19404199Pending
- 3Alpha-OH-5Alpha-Pregnan-20-One Compositions and Methods for Treating CNS DisordersApr 30, 2026 · Application 17723203Pending
- Oral Brexanolone Compositions and Methods of Preparation and UseMar 17, 2026 · US 12,576,090Granted
- Method and Composition for Treating Non-Cirrhotic NashFeb 24, 2026 · US 12,558,361Granted
- Compositions and Methods for Treating CNS DisordersJan 20, 2026 · US 12,527,805Granted
- Testosterone Dodecanoate Compositions and MethodsJan 20, 2026 · US 12,527,803Granted
- Hydroxyprogesterone Caproate Compositions and Methods of Use in Preventing Preterm BirthDec 23, 2025 · US 12,502,396Granted
- Oral Allopregnanolone Compositions and Methods of UseSep 9, 2025 · US 12,409,185Granted
- (17-)-3-Oxoandrost-4-EN-17-YL Dodecanoate Compositions and Methods of Preparation and UseJul 8, 2025 · US 12,351,600Granted
- Steroidal Testosterone Ester Compositions and Preparation ThereofJun 12, 2025 · Application 18598151Pending
- Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyJun 3, 2025 · US 12,318,396Granted
- Composition And Method For Oral Delivery Of Androgen ProdrugsMay 27, 2025 · US 12,310,978Granted
- Oral Testosterone TherapyMay 20, 2025 · US 12,303,517Granted
- Testosterone Dodecanoate Compositions and MethodsMar 25, 2025 · US 12,257,257Granted
- Compositions and Methods for Treating CNS DisordersJan 28, 2025 · US 12,208,103Granted
- Oral Allopregnanolone Compositions and Methods of UseJan 7, 2025 · US 12,186,327Granted
- Bioavailable Solid State (17-Beta)-Hydroxy-4-Androsten-3-One EstersDec 24, 2024 · US 12,171,770Granted
- Oral Testosterone TherapyDec 10, 2024 · US 12,161,651Granted
- Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyDec 3, 2024 · US 12,156,881Granted
- Liver DiseaseNov 26, 2024 · US 12,150,945Granted
- Liver DiseaseSep 24, 2024 · US 12,097,207Granted
- Oral Allopregnanolone Compositions and Methods of UseAug 1, 2024 · Application 18619033Pending
- Fixed Dose Oral Testosterone Undecanoate Compositions and Use ThereofJun 18, 2024 · US 12,011,503Granted
- Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyMay 30, 2024 · Application 18437438Pending
- Oral Testosterone TherapyMay 28, 2024 · US 11,992,496Granted
- Compositions and Methods for Treating CNS DisordersMay 16, 2024 · Application 17929895Pending
- Oral Allopregnanolone Compositions and Methods of UseApr 30, 2024 · US 11,969,434Granted
- Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyMar 19, 2024 · US 11,931,367Granted
- Bioavailable Solid State (17-Beta)-Hydroxy-4-Androsten-3-One EstersJan 16, 2024 · US 11,872,235Granted
- Steroidal CompositionsJan 11, 2024 · Application 18467366Pending
- Method and Composition for Treating EpilepsyDec 7, 2023 · Application 18328388Pending
- (17-ß)-3-OXOANDROST-4-EN-17YL Tridecanoate Compositions And Methods Of Their Preparation And UseJul 25, 2023 · US 11,707,467Granted
- Oral Testosterone Non-Undecanoate TherapyJun 13, 2023 · US 11,672,807Granted
- 17-HYDROXYPROGESTERONE Ester-containing Oral Compositions And Related MethodsFeb 28, 2023 · US 11,590,147Granted
- Oral Testosterone Undecanoate TherapyJan 24, 2023 · US 11,559,530Granted
- Compositions and Methods for Treating CNS DisordersOct 25, 2022 · US 11,478,485Granted
- 17-HYDROXYPROGESTERONE Ester-containing Oral Compositions And Related MethodsOct 18, 2022 · US 11,471,470Granted
Related companies, and why
- RegenX Science Inc.Similar federal contract value in Biotech · null in contracts
- EUPRAXIA PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- LATTICE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- ADMA PLASMA BIOLOGICS, INC.Similar federal contract value in Biotech · null in contracts
- Pahr Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Achelios Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .